Skip to main content
SpringerLink
Log in

HCV Recurrence: Predictors and Outcomes After Liver Transplantation

  • Chapter
Disease Recurrence After Liver Transplantation

  • 655 Accesses

Abstract

In western countries, hepatitis C virus (HCV)-related end-stage cirrhosis represents the most frequent indication for liver transplantation (LT) (www.unos.org, www.eltr.org). Reinfection occurs invariably in those who are viremic at transplantation resulting in recurrent disease with uncertain outcome. Several factors, in particular, donor age, have shown to influence the natural history of HCV post-transplantation. Understanding which factors determine disease and patient outcomes, which modifications can be implemented to improve results, the feasibility of use and diagnostic reliability of available tools for monitoring disease evolution, and the place of retransplantation (RT) are still essential aspects in the setting of limited access to new antiviral drugs as well as for those failing new antiviral regimes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Hill AM, Saleem J, Heath KA, et al. Effects of Sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. American Association for the Study of Liver Diseases (AASLD) liver meeting, Boston, Oct 2014, abstract 44; Hepatology. 2014;60(S1):219A.

    Google Scholar 

  2. Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt1):329–37.

    Article  PubMed  Google Scholar 

  3. Van der Meer AJ, Heathcote EJ, Janssen HLA. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.

    Article  PubMed  Google Scholar 

  4. García-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.

    Article  PubMed  Google Scholar 

  5. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28–34.

    Article  PubMed  Google Scholar 

  6. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.

    Article  CAS  PubMed  Google Scholar 

  7. Berenguer M, Aguilera V, Prieto M, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl. 2003;9(11):1152–8.

    Article  PubMed  Google Scholar 

  8. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830–6.

    Article  CAS  PubMed  Google Scholar 

  9. Bacchetti P, Boylan RD, Terrault N, et al. Non-Markov multistate modelling using time-varying covariates, with application to progression of liver fibrosis due to hepatitis C following liver transplantation. Int J Biostat. 2010;6(1):Article 7.

    Google Scholar 

  10. Wiesner RH, Sorrell M, Villamil F. Report of the first international liver transplant society consensus conference on liver transplantation and hepatitis C. Liver Transpl. 2003;9:S1–9.

    Article  PubMed  Google Scholar 

  11. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–35.

    Article  PubMed  Google Scholar 

  12. Verna EC, Abdelmessih R, Salomao MA, et al. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl. 2013;19:78–88.

    Article  PubMed  Google Scholar 

  13. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology. 2000;32:852–8.

    Article  CAS  PubMed  Google Scholar 

  14. Forman LM, Lewis J, Berlin J, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889–96.

    Article  PubMed  Google Scholar 

  15. Ghabril M, Dickson R, Wiesner R. Improving outcomes of liver retransplantation: an analysis of trends and the impact of hepatitis C infection. Am J Transplant. 2008;8:404.

    Article  CAS  PubMed  Google Scholar 

  16. Prieto M, Berenguer M, Rayón JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–6.

    Article  CAS  PubMed  Google Scholar 

  17. Guido M, Fagiuoli S, Tessari G, et al. Histology predicts cirrhotic evolution of post transplant hepatitis C. Gut. 2002;50(5):697–700.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl. 2004;10:1240–7.

    Article  PubMed  Google Scholar 

  19. Selzner N, Renner EL, Selzner M, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88(10):1214–21.

    Article  CAS  PubMed  Google Scholar 

  20. Berenguer M, Aguilera V, Prieto M, et al. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. Liver Transpl. 2009;15(7):738–46.

    Article  PubMed  Google Scholar 

  21. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008;14(12):1766–77.

    Article  PubMed  Google Scholar 

  22. Blasco A, Forns X, Carrión JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology. 2006;43(3):492–9.

    Article  PubMed  Google Scholar 

  23. Carrión JA, Torres F, Crespo G, et al. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology. 2010;51(1):23–34.

    Article  PubMed  CAS  Google Scholar 

  24. Manousou P, Burroughs AK, Tsochatzis E, et al. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol. 2013;58:962–8.

    Article  CAS  PubMed  Google Scholar 

  25. Manousou P, Cholongitas E, Samonakis D, et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014;63(6):1005–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Calvaruso V, Dhillon AP, Tsochatzis E, et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. J Gastroenterol Hepatol. 2012;27(7):1227–32.

    Article  PubMed  Google Scholar 

  27. Samuel D, Forns X, Berenguer M, et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12–14, 2006). J Hepatol. 2006;45:127–43.

    Article  PubMed  Google Scholar 

  28. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation. J Hepatol. 2005;42(4):448–56.

    Article  PubMed  Google Scholar 

  29. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl. 2003;9:S63–6.

    Article  PubMed  Google Scholar 

  30. Foxton MR, Quaglia A, Muiesan P, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2006;6(8):1922–9.

    Article  CAS  PubMed  Google Scholar 

  31. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patient co-infected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2008;47:407–17.

    Article  CAS  PubMed  Google Scholar 

  32. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002;36:202–10.

    Article  PubMed  Google Scholar 

  33. Feng S, Goodrivh NP, Btagg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant. 2006;6:783–90.

    Article  CAS  PubMed  Google Scholar 

  34. Berenguer M. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14 Suppl 2:S45–50.

    Article  PubMed  Google Scholar 

  35. Lai JC, O’Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl. 2012;18:532–8.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23:1038–44.

    Article  PubMed  Google Scholar 

  37. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53:317–24.

    Article  CAS  PubMed  Google Scholar 

  38. Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55:322–7.

    Article  CAS  PubMed  Google Scholar 

  39. Shackel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C related liver failure post-liver transplantation. Liver Transpl. 2009;15(7):709–18.

    Article  PubMed  Google Scholar 

  40. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008;14 Suppl 2:S36–44.

    Article  PubMed  Google Scholar 

  41. Feray C, Gigou M, Samuel D, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology. 1995;108(4):1088–96.

    Article  CAS  PubMed  Google Scholar 

  42. Feray C, Caccamo L, Alexander GJM, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology. 1999;117(3):619–25.

    Article  CAS  PubMed  Google Scholar 

  43. Pageaux GP, Ducos J, Mondain AM, et al. Hepatitis C virus genotypes and quantitation of serum hepatitis C virus RNA in liver transplant recipients: relationship with severity of histological recurrence and implications in the pathogenesis of HCV infection. Liver Transpl Surg. 1997;3(5):501–5.

    Article  CAS  PubMed  Google Scholar 

  44. Taner CB, Bulatao IG, Keaveny AP, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 2011;17:641–9.

    Article  PubMed  Google Scholar 

  45. Zekry A, Whiting P, Crawford DH, et al. Liver transplant for HCV-associated liver cirrhosis: recipient predictors of outcomes in population with significant genotypes 3 and 4 distribution. Liver Transpl. 2003;9:339–47.

    Article  CAS  PubMed  Google Scholar 

  46. Wali MH, Heydtmann M, Harrison RF, et al. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl. 2003;9:796–804.

    Article  PubMed  Google Scholar 

  47. Terrault NA, Shiffman ML, Lok AS, et al. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl. 2007;13(1):122–9.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Terrault NA, Stravitz RT, Lok AS, et al. Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. Hepatology. 2014;59(4):1311–9.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Tao R, Ruppert K, Cruz Jr RJ, et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl. 2010;16(11):1288–95.

    Article  PubMed  Google Scholar 

  50. Uemura T, Ramprasad V, Hollenbeak CS, et al. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12(4):984–91.

    Article  CAS  PubMed  Google Scholar 

  51. Wells M, Croome KM, Janik T, et al. Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2014;28(2):103–8.

    PubMed Central  PubMed  Google Scholar 

  52. Belli LS, Burroughs AK, Burra P, et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transpl. 2007;13:733–40.

    Article  PubMed  Google Scholar 

  53. Lai JC, Verna EC, Brown RS, et al. Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology. 2011;54:418–24.

    Article  PubMed Central  PubMed  Google Scholar 

  54. Lai JC, Feng S, Roberts JP, et al. Gender differences in liver donor quality are predictive of graft loss. Am J Transplant. 2011;11(2):296–302.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  55. Hanouneh IA, Feldstein AE, McCullough AJ, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl. 2008;14(9):1287–93.

    Article  PubMed  Google Scholar 

  56. Brandman D, Pingitore A, Lai JC, et al. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl. 2011;17:1380–6.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Veldt BJ, Poterucha JJ, Watt KD, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009;9:1406–13.

    Article  CAS  PubMed  Google Scholar 

  58. Saxena V, Lai JC, O’Leary JG, et al. Recipient-donor race mismatch for African American liver transplant patients with chronic hepatitis C. Liver Transpl. 2012;18:524–53.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Layden JE, Cotler SJ, Grim SA, et al. Impact of donor and recipient race on survival after hepatitis C-related liver transplantation. Transplantation. 2012;93:444–9.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl. 2012;18:716–26.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Moreno S, Fortun J, Quesada C, et al. Liver Transplantation in HIV-infected recipients. Liver Transpl. 2005;11:76–81.

    Article  PubMed  Google Scholar 

  62. Borentain P, Colson P, Dhiver C, et al. Successful treatment with sofosbuvir of fibrosing cholestatic hepatitis C after liver transplantation in HIV-HCV coinfected patient. Antivir Ther. 2015;20(3):353–6. doi:10.3851/IMP2841.

    Article  PubMed  Google Scholar 

  63. Humar A, Washburn K, Freeman R, et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl. 2007;13(10):1422–7.

    Article  PubMed  Google Scholar 

  64. Tong CY, Bakran A, Williams H, et al. Association of tumour necrosis factor alpha and interleukin 6 levels with cytomegalovirus DNA detection and disease after renal transplantation. J Med Virol. 2001;64:29–34.

    Article  CAS  PubMed  Google Scholar 

  65. Bosch W, Heckman MG, Pungpapong S, et al. Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation. Transplantation. 2012;93(7):723–8.

    Article  PubMed  Google Scholar 

  66. Gedaly R, Clifford TM, McHugh PP, et al. Prevalent immunosuppressive strategies in liver transplantation for hepatitis C: results of a multi-center international survey. Transpl Int. 2008;21:867–72.

    Article  PubMed  Google Scholar 

  67. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol. 2006;44:717–22.

    Article  CAS  PubMed  Google Scholar 

  68. Rubín A, Berenguer M. Liver transplantation: personalized immunosuppression in patients with hepatitis C virus infection and hepatocellular carcinoma. Gastroenterol Hepatol. 2013;36(1):48–57.

    Article  PubMed  Google Scholar 

  69. Samonakis DN, Germani G, Burroughs AK. Immunosuppression and HCV recurrence after liver transplantation. J Hepatol. 2012;56(4):973–83.

    Article  CAS  PubMed  Google Scholar 

  70. Samonakis DN, Triantos CK, Thalheimer U, et al. Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl. 2005;11:384–5.

    Article  Google Scholar 

  71. O’Leary JG, Trotter JF, Neri MA, et al. Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation. Proc (Baylor Univ Med Cent). 2011;24:187–91.

    Google Scholar 

  72. Irish W, Arcona S, Bowers D, et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. Am J Transplant. 2011;11(8):1676–85.

    Article  CAS  PubMed  Google Scholar 

  73. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl. 2004;10:1258–62.

    Article  PubMed  Google Scholar 

  74. Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2 T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006;12:1464–72.

    Article  PubMed  Google Scholar 

  75. Berenguer M, Aguilera V, Prieto M, et al. Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients. Liver Transpl. 2006;12:762–7.

    Article  PubMed  Google Scholar 

  76. Berenguer M, Aguilera V, San Juan F, et al. Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus positive recipients. Transplantation. 2010;90:1204–9.

    Article  CAS  PubMed  Google Scholar 

  77. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a metaanalysis. Liver Transpl. 2007;13:21–9.

    Article  PubMed  Google Scholar 

  78. Duvoux C, Firpi R, Grazi GL, et al. Recurrent hepatitis C virus infection post liver transplantation: impact of choice of calcineurin inhibitor. Transpl Int. 2013;26(4):358–72.

    Article  CAS  PubMed  Google Scholar 

  79. Garcia-Saenz-de-Sicilia M, Mukherjee S. The adverse pharmacology of calcineurin inhibitors and their impact on hepatitis C recurrence after liver transplantation: implications for clinical practice. Expert Rev Clin Pharmacol. 2012;5(5):587–93.

    Article  CAS  PubMed  Google Scholar 

  80. Yoshida EM, Lilly LB, Marotta PJ, et al. Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. Ann Hepatol. 2013;12(2):282–93.

    CAS  PubMed  Google Scholar 

  81. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226–31.

    Article  PubMed  Google Scholar 

  82. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med. 1996;334:815–20.

    Article  CAS  PubMed  Google Scholar 

  83. Berenguer M, Prieto M, Cordoba J, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepatol. 1998;28:756–63.

    Article  CAS  PubMed  Google Scholar 

  84. Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011;17:1394–403.

    Article  PubMed  Google Scholar 

  85. Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl. 2013;19:896–906.

    Article  PubMed  Google Scholar 

  86. Llado L, Fabregat J, Castellote J, et al. Impact of immunosuppression without steroids on rejection and hepatitis C virus evolution after liver transplantation: results of a prospective randomized study. Liver Transpl. 2008;14:1752–60.

    Article  PubMed  Google Scholar 

  87. Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl. 2004;10:52–7.

    Article  PubMed  Google Scholar 

  88. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C. Liver Transpl. 2002;8:40–6.

    Article  PubMed  Google Scholar 

  89. Germani G, Pleguezuelo M, Villamil F, et al. Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant. 2009;9:1725–31.

    Article  CAS  PubMed  Google Scholar 

  90. Patsenker E, Schneider V, Ledermann M, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388–98.

    Article  CAS  PubMed  Google Scholar 

  91. Watt KD, Dierkhising R, Heimbach JK, et al. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. Liver Transpl. 2012;18:1029–36.

    Article  PubMed  Google Scholar 

  92. Levy G, Schmidli H, Punch J, et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl. 2006;12:1640–8.

    Article  PubMed  Google Scholar 

  93. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant. 2012;12:3008–20.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  94. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl. 2001;7:1064–70.

    Article  CAS  PubMed  Google Scholar 

  95. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl. 2002;8:123–31.

    Article  PubMed  Google Scholar 

  96. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002;8:132–42.

    Article  PubMed  Google Scholar 

  97. Moonka DK, Kim D, Kapke A, et al. The influence of induction therapy on graft and patient survival in patients with and without hepatitis C after liver transplantation. Am J Transplant. 2010;10(3):590–601.

    Article  CAS  PubMed  Google Scholar 

  98. McCaughan GW, Zekry A. Mechanisms of HCV reinfection and allograft damage following liver transplantation. J Hepatol. 2004;40:368–74.

    Article  PubMed  Google Scholar 

  99. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology. 1999;29(2):365–70.

    Article  CAS  PubMed  Google Scholar 

  100. Rosen HR, Prieto M, Casanovas-Taltavull T, et al. Validation and refinement of survival models for liver retransplantation. Hepatology. 2003;38:460–9.

    Article  PubMed  Google Scholar 

  101. Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl. 2003;9:1019–24.

    Article  PubMed  Google Scholar 

  102. Northup PG, Pruett TL, Kashmer DM, et al. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transpl. 2007;7:1984–8.

    Article  CAS  Google Scholar 

  103. Markmann JF, Gornbein J, Markowitz JS, et al. A simple model to estimate survival after retransplantation of the liver. Transplantation. 1999;67:422–30.

    Article  CAS  PubMed  Google Scholar 

  104. Andres A, Gerstel E, Combescure C, et al. A score predicting survival after liver retransplantation for hepatitis C virus cirrhosis. Transplantation. 2012;93(7):717–22.

    Article  PubMed  Google Scholar 

  105. Pfitzmann R, Benscheidt B, Langrehr JM, et al. Trends and experiences in liver retransplantation over 15 years. Liver Transpl. 2007;13:248–57.

    Article  PubMed  Google Scholar 

  106. Kashyap R, Jain A, Reyes J, et al. Causes of retransplantation after primary liver transplantation in 4000 consecutive patients: 2-19 years follow-up. Transplant Proc. 2001;33:1486–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  107. Biggins SW, Terrault NA. Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transpl. 2003;9:236–8.

    Article  PubMed  Google Scholar 

  108. Carrión JA, Navasa M, Forns X. Retransplantation in patients with hepatitis C recurrence alter liver transplantation. J Hepatol. 2010;53:962–70.

    Article  PubMed  Google Scholar 

  109. Biggins SW, Gralla J, Dodge JL, et al. Survival benefit of repeat liver transplantation in the United States: a serial MELD analysis by hepatitis C status and donor risk index. Am J Transplant. 2014;14(11):2588–94.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  110. Briceño J, Cruz-Ramírez M, Prieto M, et al. Use of artificial intelligence as an innovative donor-recipient matching model for liver transplantation: results from a multicenter Spanish study. J Hepatol. 2014;61(5):1020–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hepatology Unit and Ciberehd, La Fe Hospital, Valencia, Spain

    Angel Rubín & Marina Berenguer

  2. University of Medicine, Valencia, Spain

    Marina Berenguer

  3. Hospital Universitari i Politècnic La Fe (Torre F-5), Avinguda de Fernando Abril Martorell, n° 106, Valencia, 46026, Spain

    Marina Berenguer

Authors
  1. Angel Rubín
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marina Berenguer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marina Berenguer .

Editor information

Editors and Affiliations

  1. Institute for Digestive Health & Liver Disease, Mercy Medical Center & University of Maryland School of Medicine, Baltimore, Maryland, USA

    Paul J. Thuluvath

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rubín, A., Berenguer, M. (2016). HCV Recurrence: Predictors and Outcomes After Liver Transplantation. In: Thuluvath, P. (eds) Disease Recurrence After Liver Transplantation. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2947-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-2947-4_3

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-2946-7

  • Online ISBN: 978-1-4939-2947-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation